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Background. The (anti neutrophil cytoplasmatic autoantibody ANCA), associated small vessel vasculitides (ASVV) are relapsing-
remitting inﬂammatory disorders, involving various organs, such as the kidneys. (Monocyte chemoattractant protein 1 MCP-1)
hasbeenshowntobelocallyupregulatedinglomerulonephritisandrecentstudieshavepointedoutMCP-1asapromisingmarker
of renal inﬂammation. Here we measure urinary cytokine levels in diﬀerent phases of disease, exploring the possible prognostic
value of MCP-1, together with (interleukin 6 IL-6), (interleukin 8 IL-8) and (immunoglobulin M IgM). Methods.M C P - 1 ,I L - 6
and IL-8 were measured using commercially available ELISA kits, whereas IgM in the urine was measured by an in-house ELISA.
Results. The MCP-1 levels in urine were signiﬁcantly higher in patients in stable phase of the disease, compared with healthy
controls. Patients in stable phase, with subsequent adverse events; had signiﬁcantly higher MCP-1 values than patients who did
not. MCP-1 and IgM both tended to be higher in patients relapsing within three months, an observation, however, not reaching
statistical signiﬁcance. Urinary levels of IL-6 correlated with relapse tendency, and IL-8 was associated with disease outcome.
Conclusions. Patients with ASVV have raised cytokine levels in the urine compared to healthy controls, even during remission.
Raised MCP-1 levels are associated with poor prognosis and possibly also with relapse tendency. The association with poor
prognosis was stronger for U-MCP-1 than for conventional markers of disease like CRP, BVAS, and ANCA, as well as compared
to candidate markers like U-IgM and U-IL-8. We thus consider U-MCP-1 to have promising potential as a prognostic marker in
ASVV.
Copyright © 2009 Sophie Ohlsson et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
(Antineutrophilic cytoplasmatic autoantibodies, ANCA)-
associated small vessel vasculitides (ASVVs) is a group of
inﬂammatory disorders, characterized by inﬂammation and
necrosis of blood vessels and frequent granuloma formation
[1]. The patients make autoantibodies against proteins
present in the granules of neutrophils and monocytes,
mainly proteinase 3 (PR3) and myeloperoxidase (MPO)
[2]. The disorders, including Wegener’s Granulomatosis
(WG) and microscopic polyangiitis (MPA), have a relapsing-
remitting progression and a high mortality if untreated. The
pathogenesis is still poorly understood. As the ANCA titer
correlates with disease activity in some studies [3, 8], a
pathogenic role for the autoantibodies has been implicated.
Proinﬂammatory cytokines, such as tumor necrosis factor
alpha (TNF-α), interleukin (IL)-1β, and IL-8, have been
foundtobeelevatedsystemicallyandlocallyatinﬂammatory
sites in WG [9–12]. Moreover, a pathogenic role has been
attributed to IL-8 in ANCA-associated glomerulonephritis
[10].Inanearlierstudy,welookedatthecirculatingcytokine
proﬁle in ASVV in stable remission as well as in diﬀerent
degrees of activity [13]. Our main ﬁnding was that patients
with ASVV have raised circulating cytokine levels, compared
tohealthycontrols,evenduringstableremission—indicating
that there is persistent disease activity, kept under control by
inhibitory anti-inﬂammatory cytokines.
Previous studies have shown that the renal function at
diagnosis is a strong predictor not only for renal survival
but also for patient survival in ASVV [4, 14, 15]. Other2 Mediators of Inﬂammation
factors have also been reported to predict outcome in ASVV
such as severity of the disease at diagnosis, treatment related
infections, alpha 1 antitrypsin deﬁciency, high levels of
PR3-ANCA measured by capture ELISA, and low levels of
thrombocytes [16–20]. However these ﬁndings have usually
n o tb e e nc o n ﬁ r m e di nr e p e a t e di n v e s t i g a t i o n s .P r o t e i n u r i a ,
severe interstitial ﬁbrosis, and glomerulosclerosis which are
known to predict outcome in chronic proteinuric glomeru-
lonephritides have also been found to be important risk
factors for development of renal failure in ASVV [14, 15, 21,
22].
In other glomerulonephritides, not associated with vas-
culitis, elevated urinary excretion of high molecular weight
proteins, for example IgM, has been found to be a better
predictor of renal outcome than the degree of albuminuria
[23–25]. Tencer et al. reported high urinary IgM excretion in
many patients with crescent glomerulonephritis and ASVV
[7], and a later study investigated the prognostic signiﬁcance
of urinary IgM excretion in ASVV compared to other known
or putative prognostic markers [26]. In conclusion, for
patients with ANCA-associated small vessel vasculitis, a high
level of urine IgM excretion at time of diagnosis was strongly
associated with the development of end stage renal disease,
and in addition to old age, also predicted patient survival.
MCP-1 (CCL2) is a chemokine which speciﬁcally attracts
blood monocytes and tissue macrophages to its source,
via interaction with its cell surface receptor, CCR2 [27].
Renal cells produce MCP-1 in response to various pro
inﬂammatory stimuli, and the expression has been shown
to be locally up regulated in glomerulonephritis [28]a sw e l l
as in diabetic nephropathy [29]. Indirectly, by macrophage
recruitment, and also via direct induction of a ﬁbrotic
response in glomerular mesangial cells—MCP-1 has the
potential to drive the process of renal ﬁbrosis [30]. There
are several studies on MCP-1 in diabetes and diabetic
nephropathy [30], as well as in SLE [31], whereas there is
so far only one clinical study exploring the signiﬁcance of
this protein in ASVV [5]. Other cytokines, like IL-8 and IL-
6 have been more thoroughly investigated, and U-IL-8 has
been suggested as a candidate marker of renal involvement
[10].
In this study we measured the levels in urine of MCP-
1, IL-8 and IL-6, together with IgM, in well-characterized




2.1. Patients. Between February 2001 and March 2003, all
patients with ASVV, according to the Chapel Hill Consensus
Conference disease deﬁnition, visiting the department of
Nephrology, Lund University Hospital, were invited to be
included. Patients with dialysis treatment or cancer were
not included. No samples were taken from patients when
having ongoing viral or bacterial infections. The patients
were followed during four to six years by regular visits at the
clinic. Clinical status, (Birmingham vasculitis activity score
BVAS), relapses as well as the development of any critical
Table 1: Patient characteristics.
Remission Smouldering Relapse
No. of patients 57 25 17
%f e m a l e 74 86 62
Age 63 (19–88) 65 (26–82) 60 (26–83)
% MPO/PR3/seroneg 28/63/9 35/47/8 24/62/14
% relapse within 3M 10 24 —
% develop critical OD 12 32 —
BVAS 0 (0-1) 3 (2–5) 6 (2–11)






P-Creatinine (μ mol/l) 93
(45–498) 81 (52–317) 90
(61–189)
P-CRP (mg/l) 5 (0–57) 9 (0–61) 14 (5–160)
U-PHC (mg/l) 5.6
(0–73.7) 5.7 (0–37.6) 15.9
(5.1–36.1)
MPO = myeloperoxidase-ANCA positive, PR3 = proteinase 3-ANCA
positive, seroneg = seronegative, M = months, OD = organ damage, BVAS
= Birmingham vasculitis activity score, CRP = C-reactive protein, PHC =
protein HC/β2-microglobulin. Age, BVAS, plasma and urine measurements
are expressed as “median value (range)”.
damage (damage consistent with signiﬁcant organ failure)
according to the (vasculitis damage index VDI) or death due
to vasculitic complications was registered [32]. The patients’
status at time of sampling was classiﬁed as remission (BVAS
0-1), chronic grumbling activity (BVAS < 5) or relapse/new
disease activity (BVAS > 6). These observations were made
without access to the results of our analyses. The data
presented in tables and ﬁgures here in after are based on
the index sample of each patient, taken at inclusion in the
study. When looking at the possible connection between U-
MCP1 levels and prognosis or relapse, only patients in stable
phase of disease (remission or chronic grumbling disease)
were included. The control group consisted of healthy blood
donors (HBDs). These studies were performed with the
permission of the Ethical Committee, Lund University, and
the written informed consent of the patients. See Table 1 for
further patient characteristics.
2.2. ELISA Measurements of IL-6, IL-8, and MCP-1 in Plasma
and Urine Samples. The blood samples were taken in EDTA
tubes and immediately centrifuged, and hence plasma was
taken oﬀ and stored in −20◦C. Portions of 30mL ﬁrst
voided urine were collected in polyethylene vessels (Kebo
AB, Sweden). After the addition of 1mL of preservation
solution (containing benzamidinium chloride, EDTA, tris
(hydroxymetyl)–aminoethane and azide; resulting in stable
levels of proteins in frozen urine samples, [6]), the urine
samples were kept frozen at −20◦C until assayed.
A quantitative sandwich enzyme immunoassay from
R&D systems (Abingdon, UK), where a monoclonal anti-
body speciﬁc for IL-6, IL-8, or MCP-1 had been pre-
coated onto a microplate, was used. Brieﬂy, Assay Diluent
RD1A and Standard or sample was added to each well and
left to incubate for two hours at room temperature. The
plates were washed four times, to eliminate any unboundMediators of Inﬂammation 3
substances. Then Conjugate (a polyclonal antibody conju-
gated to horseradish peroxidase) was added to each well
for detection of the cytokine. After two hours’ incubation
at room temperature, the plates were washed four times
and Substrate Solution was added to each well. 20 minutes
incubation at room temperature allowed color development
in proportion to the amount of cytokine bound in the initial
step. Finally, Stop Solution was added to each well and the
intensity of the coloring measured. The absorbance was read
at 450nm and 570nm (correction wavelength).
2.3.U-IgM. UrineIgMwasmeasuredbyanELISAtechnique
described in detail earlier [6]. A polyclonal sheep anti-
IgM antibody was used as capture antibody, and an AP-
conjugated goat antihuman IgM antibody was used for
detection.
2.4. Cystatin C, CRP, Creatinine, Protein HC. P-Cystatin C
was measured as marker of glomerular ﬁltration and was
used for correction of cytokine levels in plasma [13]. C-
reactive protein and creatinine are conventional markers of
inﬂammation and renal function, respectively. Creatinine
was measured in both serum and urine. Protein HC was also
detected in urine.
The Clinical Chemical Laboratory at Lund University
Hospital, Lund, Sweden, performed analyses on a Hitachi
917 Pluto. Kits from Roche Diagnostics and Dako were used.
PlasmacystatinCandurineproteinHCweredetermined
by immunoturbidimetry, and plasma and urine concentra-
tions of creatinine were measured by use of a creatininase
enzyme-based procedure.
2.5. ANCA. Wieslab AB, Lund, Sweden, performed analyses
of PR3-ANCA and MPO-ANCA by routine methods [33,
34].
2.6. Statistical Analysis. All statistics were performed in
StatView 5.01. For correlation analysis, the nonparametric
Spearman’s rank correlation test was used in order to
reduce the impact of outliers. Simple regression analysis was
performed on logarithmic values, for normally distributed
parameters. Analysis of variance was done using the non-
parametric Kruskal-Wallis test and Man Whitney U-test.
3. Results
In all 82 patients with stable ASVV were included in the
study. At inclusion 57 were in remission, while 25 had
grumbling disease activity. Samples at time of relapse were
collected from an additional 17 patients—these were not
included when looking at the potential relation between
U-MCP-1 levels and outcome/relapses (Table 1). Severe
outcome, as deﬁned in the methods section, occurred in
15 patients. During followup 23 patients developed at
least one relapse, in 12 cases samples were taken within
three months before the clinical relapse. Overall there were
no statistical diﬀerences whatsoever between patients with
diﬀerent ANCA speciﬁcity. Subgrouping according to ANCA
speciﬁcity was thus considered superﬂuous, and these data
are not shown.
3.1. U-MCP-1. The urinary MCP-1 levels were signiﬁcantly
higher in patients in stable phase of the disease (n = 82),
compared with healthy controls (n = 14) (17, undetected-
191 versus 10, undetected-29pg/mmol creatinine, P<. 05);
see Table 2. Patients in stable phase, who developed critical
damage or died during the followup had signiﬁcantly higher
MCP-1 values than patients who did not (72, 6.0–145 versus
15, undet-191pg/mmol creatinine, P<. 001; n = 15,
7 patients in remission and 8 patients with smouldering
disease). There was also a tendency toward higher levels in
patients relapsing within three months (n = 12, 6 patients
in remission and 6 patients with smouldering disease), an
observation, however, not reaching statistical signiﬁcance,
see Figure 1. Raised U-MCP1 was stronger associated with
severe outcome than all of the other markers measured in
urine, see Table 3. When dividing the patients in stable phase
intotwogroups withhigh(deﬁnedas>2standarddeviations
above median value) and low U-MCP-1 levels respectively,
thepositivepredictivevalueforcriticaldamagewas70%.The
negative predictive value, that is, no critical damage if the U-
MCP-1 level was low, was 89%.
No correlation could be seen with plasma levels of MCP-
1, and there was no signiﬁcant correlation with CRP, ANCA,
BVAS, U-IL6 or U-IgM. A weak positive correlation was seen
with U-IL-8 (r = 0.3, P<. 05) and there was a strong
positive correlation with U-protein HC (r = 0.6, p<. 0001),
indicating a tubular origin, which is consistent with earlier
studies [30]. The correlation with the renal function markers
in plasma—creatinine and cystatin C—was r = 0.2, P<. 05,
and r = 0.4, P<. 01, respectively.
Until now we have repeated measurements on 10
patients, and intra individual variation in U-MCP-1 so far
seems small, although a small increase before and during
relapse seems to occur. These data are preliminary and not
shown.
Plasma measurements of MCP-1 showed raised levels
in patients compared to healthy controls, however this was
not signiﬁcant after correction for renal function (data not
shown).
3.2. U-IgM. Independent of disease activity, IgM levels in
the urine were signiﬁcantly increased in ASVV, compared
to healthy controls (9.0, 5.0–70, versus 70, 1.0–800μg/mmol
creatinine, P<. 001) see Table 2. U-IgM tended to be
higher in patients who subsequently died or developed
critical organ damage; see Figure 2. In the subgroup with
grumbling disease activity this association was statistically
signiﬁcant. IgM also tended to be higher in patients relapsing
within three months, an observation, however, not reaching
statistical signiﬁcance.
3.3. U-IL-6 and U-IL-8. Urinary levels of IL-6 and IL-8 were
higher than in healthy controls; see Table 2. U-IL-8 tended to
be associated with severe outcome, and U-IL-6 was increased
in patients with subsequent relapses; see Table 3.4 Mediators of Inﬂammation
Table 2: Urine levels of MCP-1, IgM, IL-6 and IL-8. MCP-1 = monocyte chemoattractant protein 1, IgM = immunoglobulin M, IL-6 =
interleukin 6, IL-8 = interleukin 8. All data are expressed in relation to U-creatinine. Controls = healthy blood donors.
Remission Smouldering Relapse Controls
U-MCP-1(pg/mmole) 18.8 13.8 36.0 9.9
(undetected-191.1) (undetected-144.3) (3.8–90.3) (5.4–29.0)
U-IgM(μ g/mmole) 80.0 65.0 60.0 9.0
(undetected-700.0) (1.0–800.0) (1.0–300.0) (5.0–80.0)
U-IL-6(ng/mmole) 0.9 1.0 Ud 0.7
(undetected-22.3) (undetected-5.4) (undetected-1.6) (0.4–1.4)
U-IL-8(ng/mmole) 4.0 3.5 4.4 2.4

























































































Figure 1: (a) U-MCP-1 as prognostic marker No OD: no devel-
opment of critical damage according to VDI during followup. OD:
development of critical damage according to VDI. All patients
were in stable phase of the disease when the sample was taken
(7 in remission, 8 with smouldering disease in the group who
developed OD; 50 in remission and 17 with smouldering activity
in the group who did not develop OD), presented as pg MCP-
1/mmole creatinine. The box plot shows median value, with 95%
conﬁdenceinterval.(b)U-MCP-1aspredictorofrelapseYes:relapse
within 3 months. No: no relapse within 3 months. All patients
in stable phase of the disease when the sample was taken (6
in remission and 6 with smouldering disease in the group with
subsequent relapse; 51 in remission and 19 with smouldering
activity that did not relapse), presented as pg MCP-1/mmole
creatinine. The box plot shows median value, with 95% conﬁdence
interval.
Table 3: Statistical plausibility of raised potential markers to be
associated with outcome and relapse respectively. Severe outcome
deﬁned as critical damage, according to (vasculitis damage index
VDI) and death. U = urine, MCP-1 = monocyte chemoattractant
protein 1, IgM = immunoglobulin M, IL-6 = interleukin 6, IL-8 =
interleukin 8, P = plasma, ANCA = antineutrophil cytoplasmatic
autoantibodies, CRP = C-reactive protein, BVAS = Birmingham
vasculitis activity score. For statistics, the Man Whitney U-test and
Kruskall-Wallis’ test were employed.
Severe outcome Relapse within 3 months
U-MCP-1 P <. 001 P = .08
U-IgM P = .07 P = .39
U-IL-6 P = .10 P = .04
U-IL-8 P = .05 P = .2
P-IL-6 P = .45 P <. 001
P-IL-8 P = .09 P = .2
ANCA P = .48 P = .09
CRP P = .23 P = .68
Creatinine P <. 001 P = .32
Cystatin C P <. 001 P = 0.6
BVAS P = .63 P = 0.18
4. Discussion
This is the ﬁrst study to report the prognostic signiﬁcance
of urinary MCP-1 excretion in ASVV as compared to other
markers of disease-conventional (CRP, ANCA, creatinine) as
well as new candidates (IgM, IL-6, IL-8). ). In our study
U-MCP-1 correlates with disease activity, and also seems
to be a helpful predictor of poor prognosis. This conﬁrms
and extends the ﬁndings of Tam et al. [8]. They examined
whether U-MCP-1 levels could be used in monitoring
patients’ response to therapy and concluded that reduction
ofU-MCP-1levelswasamoreusefulearlylaboratorymarker
of response to therapy than reduction of proteinuria, serum
creatinine or ANCA titer [8].
There are two main possibilities why raised U-MCP-1
maybeassociatedwithadverseoutcome.FirstU-MCP-1may
signal an ongoing sub clinical inﬂammation that in the long
run is detrimental for the patient. An alternate explanation
is that U-MCP-1 is a marker of renal tubulointerstitialMediators of Inﬂammation 5
Table 4:Correlationmatrix.U =urine,MCP-1 =monocytechemoattractantprotein1,IgM =immunoglobulinM,IL-6 =interleukin6,IL-8
= interleukin 8, ANCA = anti neutrophil cytoplasmatic autoantibodies, CRP = C-reactive protein, BVAS = Birmingham vasculitis activity
score. Markers measured in the urine are expressed in relation to U-creatinine (mmol/l). For statistics, the Spearman’s rank correlation test
and simple regression analysis were performed.
BVAS ANCA Cystatin C CRP U-MCP-1) U-IgM U-IL-8
U-IL-6 0.02ns 0.2ns 0.2 P <. 05 0.07ns 0.2ns 0.05ns 0.2 P <. 05
U-IL-8 0.05ns 0ns 0.2ns 0.1ns 0.3 P <. 05 0.1ns
U-IgM 0.07ns 0.06ns 0.3 P <. 001 −0.03ns 0.1ns



































Figure 2 :U - I g Ma sp r o g n o s t i cm a r k e rN oO D :n od e v e l o p -
ment of critical damage according to VDI during followup. OD:
development of critical damage according to VDI. All patients
in stable phase of the disease when the sample was taken (7 in
remission and 8 with smouldering disease; 50 in remission and 17
with smouldering activity in the group who did not develop OD,
presented as μg IgM/mmole creatinine. The box plot shows median
value, with 95% conﬁdence interval.
damage, which correlates to severity of renal disease at onset,
which in turn aﬀects long-term prognosis. The correlation
with U-PHC and creatinine favors the second explanation,
while the correlation with disease activity and favors the
ﬁrst. Furthermore in experimental glomerulonephritis, there
is increased glomerular synthesis of MCP-1, and systemic
administration of an anti-MCP-1 antibody has been demon-
strated to reduce the severity of acute glomerulonephritis
and subsequent scarring [35, 36]. In this study MCP-1 in
plasma was raised in general in our patients, but when
adjusting for renal function this was not signiﬁcant. There
arediﬀerentpossibleexplanationsforthisphenomenon.One
is that declined renal function is associated with greater loss
ofMCP-1intheurine.Anotherexplanationisthatcorrecting
for declined renal function is bias, because raised MCP-1
levels are per se contributing to renal damage—meaning
that it’s hard to discern what the egg is, and what the hen
is. MCP-1 in the urine most likely comes from both local
production and increased ﬁltration due to raised systemic
levels. Increased glomerular synthesis could explain the lack
of clear-cut correlation between plasma levels and urinary
levels.
In our previous study of IgM excretion in the urine in
patients with ASVV, at onset of disease, there was a strong
association with development of end stage renal disease [26].
In this study, we did not speciﬁcally look at development of
end stage renal disease—but instead looked at the overall
development of critical damage due to vasculitis. In this
setting, IgM excretion in stable patients was not so strongly
associated with severe outcome. This can be explained by
the fact that IgM in the urine represents the degree of
mechanical glomerular damage, whereas MCP-1 is actively
secreted in response to several factors of systemic as well
as local origin and has the potential of both indirect and
direct toxic inﬂuence on the renal tissue. IgM may thus
be a better marker of glomerular damage, whereas MCP-
1 adds information about ongoing inﬂammation in the
kidney, not only systemically. In stable AASV patients it is
also rare with microhematuria, another marker of ongoing
glomerular inﬂammation. The prognostic value of MCP-1
most likely comes from this protein’s role in driving the
process of ﬁbrosis and scarring—so far only shown in the
kidney [30], but logically in other organs too.
U-IL-8 has been suggested to be of value in assessing
disease activity [10], but the results of this study were
not convincing. The results for U-MCP-1 and U-IL-8 are
consistent with previous studies on other diseases, like
lupus nephritis and diabetic nephropathy—indicating the
reﬂection of basic pathophysiological mechanisms, rather
than anything else [30, 37].
In conclusion urinary excretion of MCP-1 is increased in
patientswithASVV.Thedegreeofexcretioncorrelatessignif-
icantly with patient outcome, considering critical damage or
death. The association with poor prognosis was stronger for
U-MCP-1 than for conventional markers of disease like CRP,
BVAS, and ANCA, as well as compared to candidate markers
like U-IgM and U-IL-8. We thus consider U-MCP-1 to be
a promising prognostic marker in ASVV, and perhaps this
protein is also a future therapeutic target.
Further studies are needed to evaluate and conﬁrm these
data long term and longitudinally, preferably in a bigger
patient cohort.
5. Summary
Urinary excretion of MCP-1 is increased in patients with
ASVV. The degree of excretion correlates signiﬁcantly with
patient outcome, considering critical damage or death. The
association with poor prognosis was stronger for U-MCP-1
thanforconventionalmarkersofdiseaselikeCRP,BVAS,and6 Mediators of Inﬂammation
ANCA, as well as compared to candidate markers like U-IgM
and U-IL-8. We thus consider U-MCP-1 to be a promising
prognostic marker in ASVV.
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